Literature DB >> 2827534

Recurrent tuberculosis: why do patients develop disease again? A United States Public Health Service cooperative survey.

D E Kopanoff1, D E Snider, M Johnson.   

Abstract

In October 1983, a retrospective survey was initiated to determine if patients reported to the Centers for Disease Control as having recurrent tuberculosis truly had recurrent disease and, if so, why they had developed tuberculosis again. Twenty-three health jurisdictions provided information on 800 patients diagnosed as having recurrent tuberculosis during 1981 and 1982. We found that 199 (25 per cent) of the cases did not meet the criteria for recurrent disease. Of the remaining 601 recurrent cases, 20 per cent had no chemotherapy prescribed for their previous episodes of tuberculosis, 20 per cent were prescribed inadequate or inappropriate therapy, and 33 per cent were not compliant with their prescribed therapy regimens. Patients who, during their original episode of tuberculosis, received the major portion of their medical care from physicians in private practice were more compliant than those treated by other health care providers. However, those same patients were more likely to have received inappropriate therapy than patients treated by other providers. Better patient and physician education, closer monitoring, and greater use of preventive therapy and directly observed therapy are necessary to resolve these problems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827534      PMCID: PMC1349202          DOI: 10.2105/ajph.78.1.30

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  4 in total

Review 1.  The chemotherapy of pulmonary tuberculosis: a review.

Authors:  W Fox
Journal:  Chest       Date:  1979-12       Impact factor: 9.410

2.  Treatment of tuberculosis by the nonpulmonary physician.

Authors:  R B Byrd; B R Horn; D A Solomon; G A Griggs; N J Wilder
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

3.  Productivity of prolonged follow-up after chemotherapy for tuberculosis.

Authors:  W W Stead; G H Jurgens
Journal:  Am Rev Respir Dis       Date:  1973-08

4.  Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States.

Authors:  W W Addington
Journal:  Chest       Date:  1979-12       Impact factor: 9.410

  4 in total
  7 in total

1.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Factors associated with recurrent tuberculosis more than 12 months after treatment completion.

Authors:  L Kim; P K Moonan; C M Heilig; R S Yelk Woodruff; J S Kammerer; M B Haddad
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

3.  Exogenous Reinfection as a Cause of Late Recurrent Tuberculosis in the United States.

Authors:  Julia D Interrante; Maryam B Haddad; Lindsay Kim; Neel R Gandhi
Journal:  Ann Am Thorac Soc       Date:  2015-11

Review 4.  Social and cultural factors in the successful control of tuberculosis.

Authors:  A J Rubel; L C Garro
Journal:  Public Health Rep       Date:  1992 Nov-Dec       Impact factor: 2.792

5.  Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil.

Authors:  Jonathan E Golub; Betina Durovni; Bonnie S King; Solange C Cavalacante; Antonio G Pacheco; Lawrence H Moulton; Richard D Moore; Richard E Chaisson; Valeria Saraceni
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

6.  Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study.

Authors:  Hin Moi Youn; Moon-Kyung Shin; Dawoon Jeong; Hee-Jin Kim; Hongjo Choi; Young Ae Kang
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

7.  Predictors of recurrent TB in sputum smear and culture positive adults: a prospective cohort study.

Authors:  Grace Muzanyi; Y Mulumba; Paul Mubiri; Harriet Mayanja; John L Johnson; Ezekiel Mupere
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.